Anderson TJ - Search Results

1

Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic treatment.

Forouhi P, Walsh JS, Anderson TJ, Chetty U. Forouhi P, et al. Among authors: anderson tj. Br J Surg. 1994 Feb;81(2):223-5. doi: 10.1002/bjs.1800810221. Br J Surg. 1994. PMID: 8156342 Clinical Trial.

2

An integrated view of aromatase and its inhibition.

Miller WR, Anderson TJ, Evans DB, Krause A, Hampton G, Dixon JM. Miller WR, et al. Among authors: anderson tj. J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):413-21. doi: 10.1016/s0960-0760(03)00352-2. J Steroid Biochem Mol Biol. 2003. PMID: 14623539 Review.

3

Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole.

Miller WR, Larionov A, Anderson TJ, Evans DB, Dixon JM. Miller WR, et al. Among authors: anderson tj. Pharmacogenomics J. 2012 Feb;12(1):10-21. doi: 10.1038/tpj.2010.67. Epub 2010 Aug 10. Pharmacogenomics J. 2012. PMID: 20697427

4

Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole.

Miller WR, White S, Dixon JM, Murray J, Renshaw L, Anderson TJ. Miller WR, et al. Among authors: anderson tj. Br J Cancer. 2006 Apr 10;94(7):1051-6. doi: 10.1038/sj.bjc.6603001. Br J Cancer. 2006. PMID: 16538221 Free PMC article. Clinical Trial.

5

Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience.

Miller WR, Anderson TJ, White S, Evans D, Krause A, Dixon JM. Miller WR, et al. Among authors: anderson tj. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S119-23. doi: 10.1677/erc.1.00995. Endocr Relat Cancer. 2005. PMID: 16113088 Review.

6

Aromatase inhibitors: cellular and molecular effects.

Miller WR, Anderson TJ, White S, Larionov A, Murray J, Evans D, Krause A, Dixon JM. Miller WR, et al. Among authors: anderson tj. J Steroid Biochem Mol Biol. 2005 May;95(1-5):83-9. doi: 10.1016/j.jsbmb.2005.04.010. J Steroid Biochem Mol Biol. 2005. PMID: 16002280

7

Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen.

Miller WR, Dixon JM, Macfarlane L, Cameron D, Anderson TJ. Miller WR, et al. Among authors: anderson tj. Eur J Cancer. 2003 Mar;39(4):462-8. doi: 10.1016/s0959-8049(02)00600-7. Eur J Cancer. 2003. PMID: 12751376

8

Anti-tumor effects of letrozole.

Miller WR, Anderson TJ, Dixon JM. Miller WR, et al. Among authors: anderson tj. Cancer Invest. 2002;20 Suppl 2:15-21. doi: 10.1081/cnv-120014882. Cancer Invest. 2002. PMID: 12442345 Review.

9

Neoadjuvant endocrine therapy of breast cancer: a surgical perspective.

Dixon JM, Anderson TJ, Miller WR. Dixon JM, et al. Among authors: anderson tj. Eur J Cancer. 2002 Nov;38(17):2214-21. doi: 10.1016/s0959-8049(02)00265-4. Eur J Cancer. 2002. PMID: 12441257 Review.

10

Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy.

Miller WR, Dixon JM, Cameron DA, Anderson TJ. Miller WR, et al. Among authors: anderson tj. J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):103-7. doi: 10.1016/s0960-0760(01)00149-2. J Steroid Biochem Mol Biol. 2001. PMID: 11850213

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results